Related Experiment Video
Updated: Mar 10, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Giant Cell Myocarditis: A Brief Review
1From the Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison.
Insights
Giant cell myocarditis (GCM) is a severe heart condition. Early diagnosis and cyclosporine treatment improve survival rates by reducing inflammation.
Area of Science:
- Cardiology
- Pathology
- Immunology
Background:
- Giant cell myocarditis (GCM) is a rare, aggressive cardiac disease.
- It primarily affects young to middle-aged, previously healthy individuals.
- Historically diagnosed post-mortem, advancements allow earlier detection.
Purpose of the Study:
- To highlight the critical importance of early diagnosis in GCM.
- To emphasize the role of immunosuppression in managing GCM.
- To differentiate GCM from other conditions causing cardiac giant cells.
Main Methods:
- Review of clinicopathologic features of GCM.
- Analysis of diagnostic advancements (endomyocardial biopsy, explanted hearts).
- Histologic examination as the gold standard for diagnosis.
Main Results:
- Early diagnosis of GCM is crucial for timely intervention.
- Cyclosporine-based immunosuppression shows promise in reducing inflammation.
- Improved transplant-free survival is associated with prompt treatment.
- Distinguishing GCM from other giant cell lesions is vital due to varied prognoses.
Conclusions:
- Prompt diagnosis and cyclosporine-based immunosuppression can significantly improve outcomes in GCM.
- Understanding clinicopathologic features is essential for accurate diagnosis and management.
- Further research into differentiating GCM etiologies is warranted.
Abstract:
Giant cell myocarditis (GCM) is a rapidly progressive and frequently fatal disease that mainly affects young to middle-aged previously healthy individuals. Early diagnosis is critical, as recent studies have shown that rapidly instituted cyclosporine-based immunosuppression can reduce inflammation and improve transplant-free survival. Before the 1980s, GCM was mainly a diagnosis made at autopsy. Owing to advancements in diagnostic and therapeutic options, it is now increasingly diagnosed on the basis of endomyocardial biopsies, explanted hearts, or apical wedge sections removed at the time of ventricular assist device placement. Histologic examination remains the gold standard for diagnosis; however, there are many possible etiologies for cardiac giant cells. Having a working knowledge of the clinicopathologic features that distinguish GCM from other giant cell-containing lesions is essential, since such lesions can have widely divergent management and outcome.
More Related Videos
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy

